Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 20 results found. Search for [ Biocon's chairman and managing director Kiran Mazumdar-Shaw ]

Results 1 to 20 of 20
Alokesh Bhattacharyya and Sarika Malhotra
September 11, 2015
Business Today's 12th annual listing of women achievers. We drew up a long list of over 150 women and then shortlisted 55 contenders. Finally, 25 made the cut after jury deliberations.


Team BT
September 5, 2015
A brief look at the women in BT's top league.


Shweta Punj, Anilesh S. Mahajan Venkatesha Babu and Nevin John
February 12, 2015
A million Indians join the workforce every month. What can Arun Jaitley's Budget and Narendra Modi's Make in India do for them?


E. Kumar Sharma
May 31, 2014
In the seven years since, Mylan Inc has invested around $3 billion on acquisitions in India. It now regards India not just as a global sourcing hub, but also as a market.


E Kumar Sharma
April 3, 2014
Biocon CMD Kiran Mazumdar-Shaw told Business Today that the pharmaceutical major \"has not been issued any injunction on Vildagliptin; nor has Biocon launched the product in India. There is no impact on our immediate plans for this product.\"


Kiran Mazumdar-Shaw
February 17, 2014
Biocon chairman and managing director Kiran Mazumdar-Shaw says industry was not expecting much from the budget in the first place.  However, even the relief measures announced for the manufacturing sector, automobiles, blood banks and others, are token measures, feels Mazumdar-Shaw.


PTI
New Delhi, January 23, 2014
The growth for this quarter has been led by the company's flagship drug brands - Basalog, Insupen, BioMab EGFR and Abraxane.


K.R. Balasubramanyam
September 9, 2013
Globally renowned as an outsourcing hub, Bangalore has its share of problems too. Business Today brought together a dozen CEOs to brainstorm solutions to the city's problems.


BT Online Bureau
New Delhi, July 26, 2013
Biocon has reported a 18.65 per cent rise in consolidated net profit at Rs 93.50 for the first quarter ended June 30, mainly on account of strong performance in the biopharma segment.


PTI
New Delhi, April 26, 2013
Biocon has reported an over two-fold jump in its consolidated net profit to Rs 248.61 crore for the quarter ended March 31, mainly on account of exceptional income.


BT Online Bureau
New Delhi, January 26, 2013
Biocon is eyeing Rs 100 cr in sales in the next four years from psoriasis drug that it plans to launch under the brand Alzumab in the country in the current year.


PTI
New Delhi, January 25, 2013
Net sales of the biotechnology company rose to Rs 634.22 crore for the third quarter, as against Rs 516.59 crore during the same period of 2011-12 fiscal.


www.businesstoday.in
January 2, 2013
Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon Ltd, and the face of India's flowering biotechnology industry, pulls no punches in this exclusive interview to Govindraj Ethiraj on the show Bottomline, aired on Headlines Today. Edited excerpts:


E. Kumar Sharma
March 27, 2012
Compulsory licences have brought domestic and multinational pharma companies face to face. Although domestic firms are getting to make cheaper versions of patented drugs, will this be enough to cure the country of its health care ills?


PTI
Mumbai, March 13, 2012
Reacting to the news, shares of Biocon fell by 11 per cent to touch an early low of Rs 238 on the BSE in the morning trade.


Shweta Punj
August 30, 2011
Kiran Mazumdar-Shaw made several unusual choices on her way to building Biocon into a billion-dollar business


Geetanjali Shukla and Shweta Punj
August 30, 2011
Business Today held a panel discussion at The Leela, Mumbai, to debate the subject: How 'ready' are Indian marriages to accept professional women?


PTI
New Delhi, October 27, 2010
Chairman and Managing Director Kiran Mazumdar-Shaw said the investments will be in a phased manner, with $161 million going in for the first phase. The facility will be operational by 2014.


E. Kumar Sharma
October 9, 2010
Hospital-acquired infections caused by drug-resistant bacteria are the latest target of drug makers and medical suppliers.


Team BT
October 2, 2008
They span generations and are there in every field, from biscuits to banking, from HR to hospitals. Denied entry into a male bastion, they create another industry. They are the most powerful women in the corporate world.


PAGES 1 OF 1